Long-term treatment with Enspryng (satralizumab) safely and sustainably prevents relapses in adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 protein (AQP4-IgG), according to four-year data from the SAkura Phase 3 clinical trials. These benefits were observed when the therapy…
Aquaporin-4 (AQP4)
A system that stages neuromyelitis optica spectrum disorder (NMOSD) based on damage to astrocytes — the specific brain cells that are attacked in NMOSD — was recently developed by a team of researchers in Japan. While more work is needed, the system identifies four stages, largely based on astrocytopathy…
Examining the thickness of certain retinal layers in the eye, along with structural changes in the eyes’ blood vessels, can help differentiate neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS), a study found. Overall, two particular retinal layers — the peripapillary retinal nerve fiber layer…
The European Commission has approved Enspryng (satralizumab) for the treatment of people, 12 and older, with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 protein (AQP4-IgG). The approval covers Enspryng for use as a monotherapy (on its own) or in combination with other…
A branch of the European Medicines Agency has recommended that Enspryng (satralizumab) be approved to treat patients, 12 and older, with neuromyelitis optica spectrum disorder (NMOSD), who carry antibodies against the aquaporin-4 protein (AQP4-IgG). The recommendation, made by the agency’s Committee for Medicinal Products for Human Use…
Using a live cell-based assay to test for the presence of aquaporin-4 antibodies (AQP4-IgG) can accurately identify people who have neuromyelitis optica spectrum disorder (NMOSD), new research suggests. Scientists said the cell-based assay was “a highly specific diagnostic biomarker of NMOSD and did not yield false positive results.” These findings…
Treatment with Soliris (eculizumab) does not increase the risk of infections or serious infections among people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the protein aquaporin-4 (AQP4), even in those receiving accompanying immunosuppressive therapies. Those were the findings from a post hoc analysis of…
In most people with neuromyelitis optica spectrum disorder (NMOSD), autoantibodies against aquaporin-4 (AQP4) coordinate a complex series of immune activities that drive the disease. Better understanding of these disease-causing mechanisms may help in efforts to find new treatments for NMOSD patients. These mechanisms were explained in the lecture, “…
The first trimester after giving birth or ending a pregnancy is a time of high risk for women with neuromyelitis optica spectrum disorder (NMOSD), with younger patients, those with more AQP4 antibodies, or inadequate prenatal care most at risk of an attack, a study…
Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12 and older who have aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), Chugai Pharmaceutical announced. The import drug license…
Recent Posts